Cor img new mrna manufacturing facility 800x600

10.02.2021

Kaneka Eurogentec receives GMP accreditation for new mRNA manufacturing facility – COVID-19 vaccine production ongoing

Kaneka Eurogentec, a custom service and FDA inspected Contract Development and Manufacturing Organization (CDMO) received GMP accreditation by the Belgian ministry of health for the GMP manufacturing of messenger RNA (mRNA).

A new GMP facility for active pharmaceutical ingredient production

The new facility audited and accredited by Belgian Authorities will allow the production and the purification of up to 10 g scale ( up to 1 Million doses of vaccine) of RNA for use in human clinical trials and commercial supply, with potential for expansion.

Strengthening Eurogentec’s position as a leader in gene therapy

Dr. Lieven Janssens, Kaneka Eurogentec’s President and CEO, said, “Manufacturing GMP mRNA complements perfectly our ongoing GMP DNA manufacturing activities providing a one-stop-shop offering Plasmid DNA, linearization and mRNA production. It’s definitely the ambition of Kaneka Eurogentec to become the world leading CDMO for mRNA, as we are already for the production of plasmid DNA.”

Two mRNA contracts already signed

The expertise of the company for more than 25 years as CDMO for the manufacturing of GMP Biopharmaceuticals is recognized worldwide. Two customers have already signed for three mRNA sequences including for early phase COVID-19 clinical trials.

GSK continues to invest heavily in Belgium at its sites in Wavre and Rixensart

The British pharmaceutical company GSK continues to invest in its production site in Wavre and its research and development site in Rixensart...

Mithra CDMO Announces Collaboration with MedinCell for the Development of Injectable Products for Malaria and Transplant Rejection

Mithra announced a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège.

UCB invests in a bioproduction plant in Braine-l’Alleud

To support the launch of a new generation of products, UCB, the biopharmaceutical company specialized in neurology and immunology, is investing 300 million euros in the construction of an ultra-modern biological production plant at its site in Braine-l’Alleud...

Interested in updates on our insights, news and testimonials?